Details for Patent: 10,357,640

Which drugs does patent 10,357,640 protect, and when does it expire?

Patent 10,357,640 protects SINUVA and is included in one NDA.

This patent has ten patent family members in six countries.

Summary for Patent: 10,357,640

Title:	Expandable devices and methods for treating a nasal or sinus condition
Abstract:	Described here are expandable devices and methods for using them. The devices generally comprise a hub and a plurality of legs extending therefrom. In some variations, the hub may comprise one or more domed portions, tapered portions, or the like. The legs may comprise one or more straight segments, one or more curved segments, or a combination thereof. The devices may comprise one or more polymers, and/or one or more portions of the device may be configured to biodegrade. In other variations, the device may be configured to release one or more drugs therefrom. Additionally, in some variations the devices may be configured to be self-expandable from a low-profile configuration to an expanded configuration.
Inventor(s):	Anthony J. Abbate
Assignee:	Intersect ENT Inc
Application Number:	US12/779,240
Patent Claim Types: see list of patent claims	Use; Delivery; Device;

Drugs Protected by US Patent 10,357,640

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Intersect Ent Inc	SINUVA	mometasone furoate	IMPLANT;IMPLANTATION	209310-001	Dec 8, 2017		RX	Yes	Yes	10,357,640					TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT

International Family Members for US Patent 10,357,640

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2010248992
Canada	2761769
Canada	3001814
China	102573981
China	106039547
European Patent Office	2429624